Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Scientific Congress Publications
Supported by Bayer Pharmaceuticals
WSC 2026
OVERALL SOCIETAL COST OF RECURRENT STROKE: POPULATION-BASED STUDY
We quantify the 10-year cost burden of recurrent stroke after an initial stroke in the Oxford Vascular Study (OXVASC) which included patients with a first stroke (04-2002-03/2023).
Among 3,790 patients, 670 (18%) experienced a total 851 recurrent strokes. Societal cost of recurrent stroke remains substantial, both in:
- Health terms (increased 10-year mortality)
- Economic terms (increased 10-year costs)
- This is despite patients being on current best medical treatment.
The substantial societal costs associated with recurrent stroke highlight the need for more effective secondary prevention strategies.
© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.
Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.
Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.
For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/
PP-GEN-ALL-0014-1
